Results 11 to 20 of about 4,984,276 (289)

A patient with a germlineGATA2mutation and primary myelofibrosis [PDF]

Blood Advances, 2021
First description of a patient with a germline GATA2 mutation and diagnosis of primary myelofibrosis. Development of bone marrow failure on a Janus kinase inhibitor.
Cyrill Rütsche, Eugenia Haralambieva, Veronika Lysenko, Stefan Balabanov, Alexandre Theocharides   +4 more
openalex   +2 more sources

Recent advances in therapies for primary myelofibrosis. [PDF]

Fac Rev, 2023
Primary myelofibrosis (PMF), polycythemia vera (PV) and essential thrombocythemia (ET) form the classical BCR-ABL1-negative myeloproliferative neoplasms (MPNs) that are driven by a constitutive activation of JAK2 signaling.
Vainchenker W, Yahmi N, Havelange V, Marty C, Plo I, Constantinescu SN.   +5 more
europepmc   +2 more sources

Monocytosis is a powerful and independent predictor of inferior survival in primary myelofibrosis [PDF]

British Journal of Haematology, 2017
Ayalew Tefferi, Sahrish Shah, Mythri Mudireddy, Terra L. Lasho, Daniela Barraco, Curtis A. Hanson, Rhett P. Ketterling, Michelle A. Elliott, Mrinal M. Patnaik, Animesh Pardanani, Naseema Gangat   +10 more
openalex   +2 more sources

CXCL8 and its cognate receptors CXCR1/CXCR2 in primary myelofibrosis. [PDF]

Haematologica
BCR::ABL1 negative myeloproliferative neoplasms (MPN) form a distinct group of hematologic malignancies characterized by sustained proliferation of cells from multiple myeloid lineages.
Vermeersch G, Proost P, Struyf S, Gouwy M, Devos T.   +4 more
europepmc   +2 more sources

Favorable COVID‐19 course despite significant comorbidities in a ruxolitinib‐treated patient with primary myelofibrosis [PDF]

European Journal of Haematology, 2020
COVID‐19 carries a high risk of severe disease course, particularly in patients with comorbidities. Therapy of severe COVID‐19 infection has relied on supportive intensive care measures. More specific approaches including drugs that limit the detrimental
Steffen Koschmieder, Edgar Jost, Christian Cornélissen, Tobias Müller, Maximilian Schulze‐Hagen, Johannes Bickenbach, Gernot Marx, Michael Kleines, Nikolaus Marx, Tim H. Brümmendorf, Michael Dreher   +10 more
openalex   +2 more sources

Primary myelofibrosis: 2023 update on diagnosis, risk‐stratification, and management

American journal of hematology/oncology, 2023
Primary myelofibrosis (PMF) is a myeloproliferative neoplasm (MPN) characterized by stem cell‐derived clonal myeloproliferation that is often but not always accompanied by JAK2, CALR, or MPL mutations; additional features include bone marrow reticulin ...
A. Tefferi
semanticscholar   +1 more source

Higher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis

Biochemia Medica, 2023
Introduction Blood plasma represents a large reservoir of cytokines and other mediators of inflammation. Higher estimated plasma volume status (ePVS) has been shown to correlate with increased thrombotic risk in polycythemia vera patients, but its ...
M. Lucijanić, I. Krečak, E. Sorić, A. Sabljić, D. Galušić, H. Holik, V. Periša, Martina Morić Perić, I. Zekanović, R. Kušec   +9 more
semanticscholar   +1 more source

Differential prognostic impact of cytopenic phenotype in prefibrotic vs overt primary myelofibrosis

Blood Cancer Journal, 2022
Dear Editor , Cytopenias are frequent and distinctive features of primary myelo fi brosis (PMF). Anemia is the most common, has consistently been associated with shortened survival, and is an integral component of prognostic models (IPSS, DIPSS/-plus ...
G. Coltro, F. Mannelli, G. G. Loscocco, C. Mannarelli, G. Rotunno, C. Maccari, Fabiana Pancani, A. Atanasio, A. Vannucchi, P. Guglielmelli   +9 more
semanticscholar   +1 more source

IGFBP-6/sonic hedgehog/TLR4 signalling axis drives bone marrow fibrotic transformation in primary myelofibrosis

Aging, 2021
Primary myelofibrosis is a Ph-negative chronic myeloproliferative neoplasm characterized by bone marrow fibrosis and associated with the involvement of several pathways, in addition to bone marrow microenvironment alterations, mostly driven by the ...
L. Longhitano, D. Tibullo, N. Vicario, C. Giallongo, E. La Spina, A. Romano, S. Lombardo, M. Moretti, Francesco Masia, A. R. Coda, S. Venuto, Paolo Fontana, R. Parenti, G. Li Volti, M. Di Rosa, G. Palumbo, A. Liso   +16 more
semanticscholar   +1 more source

Primary myelofibrosis

Haematology, 2021
Primary myelofibrosis (PMF) is a Philadelphia negative myeloproliferative neoplasm characterized by bone marrow fibrosis, splenomegaly, anemia, constitutional symptoms, and extramedullary hematopoiesis. As a clonal hematopoietic stem cell disorder, it is
Wojciech Gorczyca
openaire   +2 more sources